CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF SYH2085 TABLETS FOR THE TREATMENT OF UNCOMPLICATED INFLUENZA IN ADULTS OFFICIALLY INITIATED IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial of SYH2085 tablets (the "**Product**") developed by the Group for the treatment of uncomplicated influenza in adults has been officially initiated at the first centre in China.

The Product is a small molecule inhibitor targeting the PA subunit of influenza virus RNA polymerase and is registered as a Class 1 chemical drug. The Product is converted *in vivo* into its main active metabolite, SYH2085A-01207, which selectively inhibits the endonuclease activity of the viral polymerase PA subunit, thereby suppressing the replication of the influenza virus.

Previously, the Group obtained the Notice of Approval for Clinical Trial of Drug for the Product issued by the National Medical Products Administration of the People's Republic of China in December 2025. Following the approval, the Group initiated the Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profiles of the Product in healthy Chinese participants. Currently, the Phase I trial data have preliminarily verified its safety, as well as its pharmacokinetic and pharmacodynamic profiles in humans, and also demonstrated that a single oral administration of the Product exhibited a favorable safety profile, good compliance and a low risk of developing drug resistance.

The clinical trial of the Product initiated on this occasion is a multi-centre, randomised, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of the Product in Chinese adult participants with uncomplicated influenza. At present, the recruitment and screening of participants for this trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 7 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.